All In Biotech

NDA 022225 · Msd Sub Merck

Bridion

Sugammadex Sodium · Intravenous

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Dec 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Dec 15, 2015

Approved uses

5

Original approval plus efficacy supplements

Registered trials

274

45 Phase 3, 13 recruiting

FAERS reports

2,731

2,306 serious, 104 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 13, 2026.

BRIDION ® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery. BRIDION is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adult and pediatric patients undergoing surgery. ( 1 )

Mechanism: BRIDION is a modified gamma cyclodextrin. It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium and vecuronium.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • BRIDION · SUGAMMADEX SODIUM EQ 500MG BASE/5ML (EQ 100MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • BRIDION · SUGAMMADEX SODIUM EQ 200MG BASE/2ML (EQ 100MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Sugammadex" as an intervention, any sponsor and status, largest first.

All 274 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anaphylactic reaction315
  • bradycardia285
  • cardiac arrest195
  • anaphylactic shock174
  • bronchospasm173
  • hypotension165
  • drug ineffective145
  • recurrence of neuromuscular blockade107
  • off label use96
  • oxygen saturation decreased95
  • drug interaction78
  • dyspnoea71

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20114
201234
201350
201435
201549
2016204
2017226
2018286
2019274
2020225
2021209
2022217
2023255
2024240
2025272
2026150

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 317 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.